Log In Sign up
The largest database of trusted experimental protocols
> Living Beings > Professional or Occupational Group > Rheumatologist

Rheumatologist

Rheumatologists are medical professionals who specialize in the diagnosis and treatment of rheumatic diseases, which affect the musculoskeletal system and connective tissues.
These physicians are experts in managing a wide range of conditions, including arthritis, lupus, gout, and other inflammatory disorders.
Rheumatologists utilize advanced diagnostic techniques, such as imaging studies and laboratory tests, to identify the underlying cause of a patient's symptoms and develop a personalized treatment plan.
Their goal is to alleviate pain, improve function, and enhance the overall quality of life for individuals living with rheumatic conditions.
Rheumatologsts play a vital role in the healthcare team, collaborating with other specialists to provide comprehensive, patient-cenetered care.
Their expertise and dedication are essential in the fight against debilitating rheumatic disorders.

Most cited protocols related to «Rheumatologist»

1
Recommendations for Rheumatoid Arthritis Disease Activity Measurement
The methods used to derive our recommendations are summarized very briefly here, but are outlined in significantly greater detail in Supplementary Appendix A (available in the online version of this article at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2151-4658). Figure 1 shows an overview of the methodology used, which included a combination of a systematic literature review, psychometric analyses, validated group methods, and physician surveys.
First, the WG conducted a systematic literature review to identify available RA disease activity measurement tools and applied initial exclusion criteria (see Supplementary Figure 1 and Supplementary Table 1, available in the online version of this article at http://onlinelibrary. wiley.com/journal/10.1002/(ISSN)2151-4658). Next, an RA disease activity measurement Expert Advisory Panel (EAP), consisting of rheumatologists with published expertise in RA disease activity measurement, was consulted to review measures meeting criteria for inclusion. The EAP ranked the recommended measures by using the Outcome Measures in Rheumatology filter on truth, discrimination, and feasibility (6 (link)). The WG then further condensed the number of measures based on a detailed review of the psychometric properties of each measure. The abbreviated measure set was then incorporated into a survey administered to practicing rheumatologists to gather information regarding usefulness, feasibility, and willingness to use in daily clinical practice. Collation of the information gathered in these steps formed the basis for the final WG recommendations.
ANDERSON J., CAPLAN L., YAZDANY J., ROBBINS M.L., NEOGI T., MICHAUD K., SAAG K.G., O’DELL J.R, & KAZI S. (2012). Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice. Arthritis care & research, 64(5), 640-647.
Publication 2012
Discrimination, Psychology Physicians Psychometrics Rheumatologist
2
Identifying Rheumatoid Arthritis Patients
Three different algorithms were used to identify patients with RA by using the Medicare claim data from 1994 to 2004: (a) beneficiaries with at least two claims associated with RA (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9 CM] code 714), (b) beneficiaries with at least three claims associated with RA, and (c) beneficiaries with at least two RA claims that were from a rheumatologist and that were separated by at least 7 days. All inpatient, outpatient, and procedure claims such as laboratory or radiologic tests were included. We identified rheumatologists with a Medicare provider specialty code in the database and verified them with the ACR membership directory. A subgroup of patients who filled at least one prescription for DMARDs over a period of 1 year after the RA diagnosis was then identified by using the data from both pharmacy benefit program and claim data for infusions. To compare baseline characteristics of the study subjects, we selected a group of beneficiaries who never had any claims for RA.
After identifying subjects by each of the algorithms, we attempted to obtain consent to review their medical record. First, the PACE program mailed a letter to the groups of subjects identified by our algorithms to inform them that they would be contacted by our research group. A letter that provided details about the study was then sent to the subjects in each of the groups and asked whether they would consent to have the study researchers review their medical records from their physicians, including doctors who treated them for arthritis. Subjects who agreed to participate in the study signed a consent and authorization form for release of medical records. Additionally, subjects were asked to complete a physician information form to identify their primary physicians as well as specialists and their contact information. We then attempted to obtain copies of medical records.
Once we received the medical records, all personal identifiers were removed from the records for protection of patients' privacy. Medical records were reviewed independently by several rheumatologists at Brigham and Women's Hospital. To minimize inter-reviewer variation in data abstraction, a structured data abstraction form was developed and pilot-tested with the principal investigator (DHS). The form included items such as the seven ACR 1987 classification criteria for RA, disease onset, other rheumatologic diagnoses, medications, and laboratory data. On the basis of these data, the reviewers assessed whether a patient met the gold standard definitions of RA: (a) diagnosis of RA by a rheumatologist and (b) fulfillment of the ACR criteria for RA. Any indication in the medical record that the diagnosing rheumatologists thought that the patient had RA at that time was counted as having 'RA diagnosis per rheumatologists'. When the patients were not seen by rheumatologists, 'RA diagnosis per rheumatologists' was made by the reviewers on the basis of the data from their medical records. When the diagnosis of RA was neither documented nor clear in their medical records, the patients were considered non-RA. Areas of disagreement or uncertainty were resolved by consensus. The study period for data collection from medical records lasted from 2004 to 2008.
Kim S.Y., Servi A., Polinski J.M., Mogun H., Weinblatt M.E., Katz J.N, & Solomon D.H. (2011). Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Research & Therapy, 13(1), R32.
Full text: Click here
Publication 2011
Antirheumatic Drugs, Disease-Modifying Arthritis Diagnosis Gold Inpatient Outpatients Patients Pharmaceutical Preparations Physicians Rheumatologist Satisfaction Specialists Vision
3
Validating Lupus Nephritis Identification
We employed inpatient and outpatient billing data from Medicaid patients at Brigham and Women's Hospital in Boston to identify lupus nephritis cases. We identified Medicaid patients seen 2000-2007 with > 2 claims for lupus (ICD9 710.0) and compared four separate ICD9-based strategies: 1: greater than 2 claims for any combination of acute or chronic glomerulonephritis (including lupus glomerulonephritis), acute or chronic renal failure, nephritis or nephrotic syndrome (including lupus nephrotic syndrome), renal failure or proteinuria (ICD-9 codes 580.-586. and 791.0), 2: greater than 2 claims for visit to a nephrologist, 3: either strategy 1 or strategy 2 and 4: both strategy 1 and strategy 2.
Independently and blinded to these results, two board-certified rheumatologists performed medical record reviews to validate lupus and lupus nephritis according to American College of Rheumatology Criteria for Systemic Lupus Erythematosus14 (link), 15 (link). To validate the presence of lupus nephritis, we employed the ACR criteria14 (link), 15 (link) referring to the presence of nephritis (persistent proteinuria > 0.5 gms/day, or > 3+ on urinalysis, or cellular casts), AND/OR biopsy-proven renal disease attributed to lupus and classified as Class-III-IV or V (focal or diffuse glomerulonephritis or membranous nephropathy) according to the World Health Organization classification16 (link) for subjects identified by each algorithm. We calculated the positive predictive value (PPV) for each strategy. PPV is calculated as the number with confirmed lupus nephritis divided by the total number subjects within that strategy.
Chibnik L.B., Massarotti E, & Costenbader K.H. (2010). Identification and Validation of Lupus Nephritis Cases Using Administrative Data. Lupus, 19(6), 741-743.
Publication 2010
Biopsy CD3EAP protein, human Cells Chronic Kidney Diseases Glomerulonephritis Inpatient Kidney Diseases Kidney Failure Lupus Erythematosus, Systemic Lupus Nephritis Lupus Vulgaris Membranous Glomerulonephritis Nephritis Nephrologists Nephrotic Syndrome Outpatients Patients Rheumatologist Urinalysis Vision
4
Developing SLE Classification Criteria
The purpose of Phase 1 was to test ANA as a potential entry criterion and identify candidate criteria that should be considered for SLE classification using both data- and expert-based methods, including the patient perspective. Phase 1a comprised a systematic literature review of Medline, Embase and the Cochrane databases with meta-regression to evaluate the operating characteristics of ANA testing for consideration as an entry criterion (12 (link)). Phase 1b consisted of a Delphi exercise of international SLE experts from the Americas, Europe and Asia (17 (link)). These experts included rheumatologists, dermatologists, nephrologists, pediatricians and non-clinical SLE researchers, providing a broad perspective. The Delphi participants were asked to nominate a broad set of items potentially useful in the classification of SLE (17 (link)). In round 2 and 3, participants rated the items from 1 (not at all appropriate) to 9 (completely appropriate) for classification of SLE. Criteria were retained if they reached a median rating of ≥6.5; i.e. at least 50% of the ratings in the high range (7, 8 or 9). Participants were also asked about the importance of ANA and histopathology for classification of SLE. Phase 1c established an international cohort of patients with early SLE or conditions mimicking SLE to identify criteria that may discriminate subjects with early (less than 12 months) disease (18 (link)). Phase 1d comprised a cross-sectional survey of SLE patients, administered via the quarterly journal of the German SLE patient organization, which asked about symptoms within one year before and after the patient’s diagnosis of SLE (19 (link)). While at a risk of recall bias and not necessarily representative of other regions worldwide, this survey was done to explicitly take a patient standpoint into account.
For phase 2 and 3, additional renowned European and North American SLE experts were nominated by the steering committee and invited to participate.
Aringer M., Costenbader K.H., Daikh D.I., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D., Kamen D.L., Jayne D., Cervera R., Costedoat-Chalumeau N., Diamond B., Gladman D.D., Hahn B.H., Hiepe F., Jacobsen S., Khanna D., Lerstrøm K., Massarotti E., McCune W.J., Ruiz-Irastorza G., Sanchez-Guerrero J., Schneider M., Urowitz M.B., Bertsias G., Hoyer B.F., Leuchten N., Tani C., Tedeschi S.K., Touma Z., Schmajuk G., Anic B., Assan F., Chan D.T., Clarke A.E., Crow M.K., Czirják L., Doria A., Graninger W.B., Halda-Kiss B., Hasni S., Izmirly P., Jung M., Kumánovics G., Mariette X., Padjen I., Pego-Reigosa J.M., Romero-Díaz J., Fernández I.R., Seror R., Stummvoll G., Tanaka Y., Tektonidou M.G., Vasconcelos C., Vital E.M., Wallace D.J., Yavuz S., Meroni P.L., Fritzler M.J., Naden R.P., Dörner T, & Johnson S.R. (2019). 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.), 71(9), 1400-1412.
Publication 2019
Clinical Investigators Dermatologist Diagnosis Europeans Mental Recall Nephrologists North American People Patients Pediatricians Rheumatologist
5
Rheumatoid Arthritis Genetic Associations
Case-control collections are listed in Table 1 and described in detail in our previous studies6 (link),7 (link),11 (link),13 (link),19 (link). Collections were composed entirely of individuals of selfdescribed European ancestry, and all cases either met the 1987 American College of Rheumatology (ACR) criteria for diagnosis of RA50 (link) or were diagnosed by board-certified rheumatologists. All RA cases were further limited to anti-CCP+ patients, or RF+ patients if anti-CCP status data were missing. The BRASS RA samples have been used in our previous 100K GWAS6 (link), but here are presented for the first time genotyped with the Affymetrix 6.0 array. In the current study, controls were matched to BRASS RA cases using principal components analysis from GWAS data from three separate studies: controls from a multiple sclerosis GWAS31 (link), controls from an age-related macular degeneration GWAS51 , and controls from a myocardial infarction GWAS52 (link). WTCCC collection controls included the 1958 birth and National Blood Service cohorts as well as non-autoimmune disease cases (bipolar disorder, cardiovascular disease, hypertension and type 2 diabetes)15 (link). All GWAS collections except WTCCC were restricted to control subjects matching cases using principal components analysis of GWAS data. All replication sample collections were composed of epidemiologically and/or geographically matched cases and controls, except NARAC II collection, which was case-control matched based on genotypes at a set of ancestry-informative markers as previously described11 (link). The eight replication samples included: (1) CCP positive cases and controls from Halifax and Toronto (CANADA-II)13 (link); (2) RF positive Dutch cases from Groningen and Nijmegen, together with geographically matched controls53 (link); (3) CCP positive Dutch cases and controls collected from the greater Amsterdam region (GENRA)54 (link); (4) North American RF positive cases and controls matched on gender, age, and grandparental country of origin from the Genomics Collaborative Initiative (GCI)4 (link); (5) CCP or RF positive Dutch cases and controls from Leiden University Medical Center (LUMC)5 (link); (6) CCP positive cases drawn from North American clinics and controls from the New York Cancer Project (together this collection is called NARAC-II)7 (link); (7) CCP or RF positive cases recruited at multiple sites in the United Kingdom by the United Kingdom Rheumatoid Arthritis Genetics (UKRAG) collaboration9 (link); and (8) CCP or RF positive cases identified by chart review from the Nurses Health Study (NHS) and matched controls based on age, gender, menopausal status, and hormone use55 (link). We used available SNP data from this and previous studies to identify genetically identical samples from the same country13 (link); we assumed these represented duplicated individuals and removed them. Institutional review boards at each collection site approved the study, and all individuals gave their informed consent.
Stahl E.A., Raychaudhuri S., Remmers E.F., Xie G., Eyre S., Thomson B.P., Li Y., Kurreeman F.A., Zhernakova A., Hinks A., Guiducci C., Chen R., Alfredsson L., Amos C.I., Ardlie K.G., Barton A., Bowes J., Brouwer E., Burtt N.P., Catanese J.J., Coblyn J., Coenen M.J., Costenbader K.H., Criswell L.A., Crusius J.B., Cui J., de Bakker P.I., De Jager P.L., Ding B., Emery P., Flynn E., Harrison P., Hocking L.J., Huizinga T.W., Kastner D.L., Ke X., Lee A.T., Liu X., Martin P., Morgan A.W., Padyukov L., Posthumus M.D., Radstake T.R., Reid D.M., Seielstad M., Seldin M.F., Shadick N.A., Steer S., Tak P.P., Thomson W., van der Helm-van Mil A.H., van der Horst-Bruinsma I.E., van der Schoot C.E., van Riel P.L., Weinblatt M.E., Wilson A.G., Wolbink G.J., Wordsworth P., Wijmenga C., Karlson E.W., Toes R.E., de Vries N., Begovich A.B., Worthington J., Siminovitch K.A., Gregersen P.K., Klareskog L, & Plenge R.M. (2010). Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature genetics, 42(6), 508-514.
Publication 2010
Age-Related Macular Degeneration Anti-Cyclic Citrullinated Protein Antibodies Autoimmune Diseases Bipolar Disorder BLOOD brass Cardiovascular Diseases Diabetes Mellitus, Non-Insulin-Dependent DNA Replication Ethics Committees, Research Europeans Genome-Wide Association Study Genotype Grandparent High Blood Pressures Hormones Malignant Neoplasms Menopause Multiple Sclerosis Myocardial Infarction North American People Nurses Patients Rheumatoid Arthritis Rheumatologist Specimen Collection

Most recents protocols related to «Rheumatologist»

1
Comprehensive AS Management System Database
The EMRMS was established in November, 2016 to assist rheumatologists in conducting ASDAS assessments and comprehensively evaluating clinical outcomes in all patients with AS attending TCVGH. The EMRMS database contains information necessary to determite ASDAS, including CRP, level and erythrocyte sedimentation rate [ESR], patient comorbidities, patient history, and family history. The reliability and validity of the data have been verified14 (link).Patients with AS were consecutively enrolled in the TCVGH-AS cohort after they received a confirmed AS diagnosis from a TCVGH rheumatologist according to the 1984 modified New York criteria10 (link). The CRP and ESR data were automatically uploaded to the TCVGH healthcare information system (HIS) to reduce human error. The baseline information, which was collected by trained nurses during the initial visit, including clinical characteristics, onset age, comorbidities at presentation (hypertension, diabetes mellitus, hyperlipidemia, hepatitis B, hepatitis C, renal insufficiency, gout, coronary artery disease, stroke, periodontal disease, osteoporosis, and tuberculosis history), periarticular extraspinal features (synovitis, enthesitis, and dactylitis) and nonarticular manifestations (psoriasis, uveitis, and IBD), family history of autoimmune disease, and patient history of arthropathy, obtained through standardized questionnaires and worksheets to ensure reproducibility and adherence to good laboratory practice. The rheumatologist in charge then confirmed patients’ clinical characteristics, and nurses assisted the patients with AS to complete the self-assessment questionnaires for disease evaluation. The following measures were used: global assessment of disease activity on a numerical rating scale (NRS) of 0–10, back pain on an NRS of 0–10, duration of morning stiffness on an NRS of 0–10, and peripheral pain or swelling on an NRS of 0–10. Before every 3-month visiting clinic, the patient would first to have blood examination. Blood reports can be uploaded to EMRMS through the HIS system, trained nurses assist patient fills out the questionnaire on EMRMS, the assessment of disease activity completed before visiting the doctor. All laboratory data, including CRP and ESR, have been uploaded to the HIS. The IT at TCVGH help "feed-forward" the patient reported outcomes to HIS, and do the auto-calculation of ASDAS-ESR, ASDAS-CRP using the ESR, CRP data in HIS, then "feed-back" these data to both HIS and EMRMS, showing the data on the summary overview "dashboard" in the EMRMS, which was shown both in HIS and the devices (iPAD handled by a nurse in charge and smartphones of patients with AS).
Huang P.J., Chen Y.H., Huang W.N., Chen Y.M., Lai K.L., Hsieh T.Y., Hung W.T., Lin C.T., Tseng C.W., Tang K.T., Chou Y.Y., Wu Y.D., Huang C.Y., Hsieh C.W., Chen Y.J., Liao Y.W., Liu Y.T, & Chen H.H. (2023). The electronic medical record management systems may improve monitoring and control of disease activity in patients with ankylosing spondylitis. Scientific Reports, 13, 3957.
Full text: Click here
Publication 2023
Arthropathy Autoimmune Diseases Back Pain BLOOD Cerebrovascular Accident Charge Nurses Coronary Artery Disease Diabetes Mellitus Diagnosis Gout Hepatitis B Hepatitis C virus High Blood Pressures Homo sapiens Hyperlipidemia Medical Devices Nurses Osteoporosis Pain Patients Periodontal Diseases Physicians Psoriasis Renal Insufficiency Rheumatologist Sedimentation Rates, Erythrocyte Self-Assessment Synovitis Tuberculosis Uveitis
2
Screening for Pulmonary Hypertension in SSc
In this single-center, retrospective cohort study, SSc patients were included, who were referred by their rheumatologists for a screening for PH at the expert center for PH at the Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Germany. SSc patients were sent with a suspicion of PH due to symptoms and laboratory or lung functional abnormalities from 2010 to 2020. The results from a part of this cohort were published before [10 (link)]. The criteria for SSc classification by the American College of Rheumatology/European League Against Rheumatism were fulfilled by all patients [11 (link)]. Patients were divided into limited (lcSSc) or diffuse cutaneous SSc (dcSSc) according to LeRoy’s criteria [12 (link)]. Patients were not included if they were underaged, not able to provide informed consent, had connective tissue diseases other than SSc, or had no data of % HRC at baseline. The routine assessment of % HRC in our clinical laboratory began in July 2014; therefore, patients assessed before could not be included in the analysis unless % HRC was determined externally.
There was no objection against the study from the ethics committee of the Medical Faculty of Heidelberg University Hospital (internal number S-126/2021). The study complied with the current version of the Declaration of Helsinki.
Xanthouli P., Gordjani O., Benjamin N., Harutyunova S., Egenlauf B., Marra A.M., Haas S., Milde N., Blank N., Lorenz H.M., Fiehn C., Ulrich S., Distler O., Grünig E, & Eichstaedt C.A. (2023). Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension. Arthritis Research & Therapy, 25, 38.
Full text: Click here
Publication 2023
Clinical Laboratory Services Collagen Diseases Congenital Abnormality Connective Tissue Diseases Ethics Committees, Clinical Europeans Faculty, Medical Lung Patients Rheumatologist
3
Pediatric Psoriasis and Musculoskeletal Involvement
This is a cross-sectional study performed between January 2019 and December 2019 by a collaboration between a tertiary pediatric dermatology and pediatric rheumatology clinic. The study group consists of pediatric Pso patients who were diagnosed in the dermatology outpatient clinics and control group is age/gender-matched randomly selected healthy volunteers.
Pso is classified according to the pattern of distribution (inverse, flexor, and seborrheic), morphology (plaque, guttat, erythrodermic, pustular, rupioid, and elephantine) and anatomic site (scalp, palmoplantar, genital, nail and, anal Pso) [9 (link)]. A pediatric dermatologist examined all patients and recorded their age at disease onset, Pso subtype, presence of nail involvement, and previous medications prescribed for cutaneous or nail Pso. Furthermore, all of them were questioned for the presence of arthralgia, arthritis, morning stiffness, hip pain, lower back pain, and heel pain in dermatology outpatient clinic. Special standardized evaluation forms were used (Appendix 1). Subsequently, pediatric patients with Pso were referred to pediatric rheumatology outpatient clinic.
Healthy controls (HCs) were the volunteers that visited pediatric outpatient clinics for either vaccination or general control. All of them were evaluated by the same questionnaire in pediatric rheumatology outpatient clinic (Appendix 2).
At pediatric rheumatology outpatient clinic, patients with Pso and healthy individuals were initially examined by two pediatric rheumatologists (HES and SGK) and two fellows (AT and FC). Demographic data, including age, sex, weight, height, family history, and comorbidities were also recorded. Subsequently, all patients and HCs were subjected to articular and entheseal examination. Modified Schober’s test was performed to all patients and HCs for the evaluation of range of motion of lumbar spine. Measurements of <6 cm were regarded as abnormal. Finally, entheseal thickness of the Achilles tendon was measured by ultrasonography (US). The US examinations were performed in a darkened room by an expert pediatric rheumatologist (NAA), using an US (Venue 40, GE Healthcare) equipped with a broadband 6–18 MHz linear probe. The rheumatologist who performed US was blinded to the patients’ diagnoses, questionnaire responses and physical examinations, as well. The thickness of the Achilles tendon was measured at longitudinal section with the probe parallel to the tendon’s alignment, near to its insertion onto the calcaneus.
The study was reviewed and approved by the Kanuni Sultan Suleyman Training and Research Hospital Clinical Research Ethics Committee (Ethics approval number: KAEK/2018.6.13) and the parents/patients gave a written consent approving to be a participant of this study.
Karadag S.G., Cakmak F., Topkarci Z., Sonmez H.E., Tanatar A., Erdugan M.K., Aldemir E., Topal N., Cakan M, & Ayaz N.A. (2023). Should children with psoriasis be consulted to a rheumatologist? Result from pediatric rheumatology-dermatology collaboration. Northern Clinics of Istanbul, 10(1), 59-66.
Publication 2023
Anus Arthralgia Arthritis Body Regions Calcaneus Dental Plaque Dermatologist Diagnosis Ethics Committees, Clinical Ethics Committees, Research Exfoliative Dermatitis Genitalia Healthy Volunteers Heel Joints Low Back Pain Nails Pain Parent Patients Pharmaceutical Preparations Physical Examination Rheumatologist Scalp Sultan Tendon, Achilles Tendons Ultrasonography Vaccination Vertebrae, Lumbar Voluntary Workers
4
Characterizing CTD-ILD Onset Patterns
After the re-analysis of rheumatological and radiological diagnoses, 27 patients were excluded for not having confirmed CTD-ILD. Clinical information and laboratory test results (Table S1) were gathered from the patient records of KUH. The results of pulmonary function tests were gathered at baseline ± three months.
The order of CTD/ILD presentation was determined from the medical records. If the patient revealed both CTD- and ILD- related symptoms, signs, or findings on the first contact to either rheumatologist or pulmonologist, the disease onset was defined as simultaneous.
The disease onset was defined as acute if the patient needed hospitalization at the onset of ILD. These patients were further divided into those who were admitted to intensive care and those admitted to pulmonology ward. If the patient was managed on an outpatient setting, the disease onset was defined as subacute/chronic. In all cases with a possibility of an acute respiratory infection, appropriate microbiological samples were collected according to the clinician’s consideration. Bronchoalveolar lavage was performed in 63.4% of the patients with an acute onset disease to exclude infections.
The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). According to Finnish legislation, no consents for inclusion are needed in retrospective register-based study. The study protocol was approved by the Ethics Committee, Hospital District of Northern Savo [statement No. 151/2015 (17/2013)]. In addition, organizational permission of KUH was obtained, which enabled data collection from the hospital registries.
Nurmi H.M., Elfving P.K., Kettunen H.P., Suoranta S.K., Järvinen H.M., Kuittinen V.A., Purokivi M.K., Kaarteenaho R.L, & Koskela H.O. (2023). Inflammatory myositis-associated interstitial lung disease can be distinguished from that associated with other connective tissue diseases. Journal of Thoracic Disease, 15(2), 311-322.
Publication 2023
Acute Disease Bronchoalveolar Lavage Ethics Committees Hospitalization Infection Intensive Care Outpatients Patients Pulmonologists Respiratory Tract Infections Rheumatologist Tests, Pulmonary Function X-Rays, Diagnostic
5
Rheumatologist-Assessed CTD Diagnosis Criteria
A rheumatologist independently evaluated laboratory findings, clinico-radiological data and other necessary examinations and re-assessed the CTD diagnoses. Patients were included in the IIM subgroup if they fulfilled either (I) the probable or definite European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and their Major Subgroups (2 (link)), or (II) the Connor’s criteria for ASyS (18 (link)). Other CTD diagnoses were confirmed by using the current International classification criteria of each disease (19 (link)-27 (link)). Eight patients with dry eyes, dry mouth, and Sjögren’s-syndrome-related antigen A/B (SSA/SSB) antibodies were included to SjS subgroup as highly probable SjS, without objective tests for dryness of mouth or eyes, but with multiple signs and symptoms supporting the diagnosis. Twenty-three patients with autoantibodies or clinical features of CTD without meeting the criteria for any specific autoimmune disease were included as UCTD (28 (link)).
Nurmi H.M., Elfving P.K., Kettunen H.P., Suoranta S.K., Järvinen H.M., Kuittinen V.A., Purokivi M.K., Kaarteenaho R.L, & Koskela H.O. (2023). Inflammatory myositis-associated interstitial lung disease can be distinguished from that associated with other connective tissue diseases. Journal of Thoracic Disease, 15(2), 311-322.
Publication 2023
Adult Antibodies Antigens Autoantibodies Autoimmune Diseases Diagnosis Dry Eye Europeans Eye Idiopathic Inflammatory Myopathies Patients Physical Examination Rheumatologist Syndrome X-Rays, Diagnostic Xerostomia

Top products related to «Rheumatologist»

1
Sas version 9 by SAS Institute
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
2
Logiq s8 by GE Healthcare
Sourced in United States, Japan, United Kingdom
The LOGIQ S8 is a diagnostic ultrasound system designed for general imaging applications. It features a high-resolution display, intuitive user interface, and advanced imaging capabilities to support clinical decision-making.
3
Mylab twice by Esaote
Sourced in Italy, Japan
MyLab Twice is a compact, portable ultrasound system designed for a range of clinical applications. The device features a high-performance imaging platform and intuitive user interface.
4
Sas v9 by SAS Institute
Sourced in United States, Austria, United Kingdom, Cameroon, Belgium, Israel, Japan, Australia, France, Germany
SAS v9.4 is a software product developed by SAS Institute. It is a comprehensive data analysis and statistical software suite. The core function of SAS v9.4 is to provide users with tools for data management, analysis, and reporting.
5
Logiq e by Philips
The Logiq E is a diagnostic ultrasound system designed for general imaging applications. It features advanced imaging technologies and a compact, ergonomic design.
6
Axio imager m2 by Zeiss
Sourced in Germany, United States, Japan, Canada, Spain, Australia, United Kingdom
The Axio Imager M2 is a high-performance microscope system designed for a wide range of applications. It features a stable, vibration-free stand, a versatile illumination system, and advanced optics to deliver high-quality images. The Axio Imager M2 is capable of supporting various imaging techniques, including brightfield, darkfield, and fluorescence microscopy.
7
Rnalater by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Japan, Lithuania, Italy, Australia, Canada, Denmark, China, New Zealand, Spain, Belgium, France, Sweden, Switzerland, Brazil, Austria, Ireland, India, Netherlands, Portugal, Jamaica
RNAlater is a RNA stabilization solution developed by Thermo Fisher Scientific. It is designed to protect RNA from degradation during sample collection, storage, and transportation. RNAlater stabilizes the RNA in tissues and cells, allowing for efficient RNA extraction and analysis.
8
Zen pro by Zeiss
Sourced in Germany, Canada
Zen Pro is a software suite designed for microscopy and imaging applications. It provides a comprehensive platform for controlling and managing various Zeiss microscope systems. The core function of Zen Pro is to enable users to capture, analyze, and process high-quality images and data from their microscopes.
9
Sas 9 by SAS Institute
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
10
Stacia meblux ccp test by Medical & Biological Laboratories
Sourced in Japan
STACIA® MEBLux™ CCP test is a laboratory equipment product used for the detection and measurement of Cyclic Citrullinated Peptide (CCP) antibodies, which are associated with rheumatoid arthritis. The core function of this test is to provide quantitative results for CCP antibodies in patient samples.

More about "Rheumatologist"

Rheumatologists are specialized medical professionals who diagnose and treat a wide range of rheumatic diseases affecting the musculoskeletal system and connective tissues.
These experts, also known as rheumatology physicians or rheumatology specialists, employ advanced techniques like imaging studies and laboratory tests to identify the underlying causes of patients' symptoms and develop personalized treatment plans.
Their goal is to alleviate pain, improve function, and enhance the overall quality of life for individuals living with conditions such as arthritis, lupus, gout, and other inflammatory disorders.
Rheumatologists collaborate closely with other healthcare providers, playing a vital role in the multidisciplinary team to deliver comprehensive, patient-centered care.
Their expertise and dedication are essential in the fight against debilitating rheumatic conditions.
Rheumatologists may utilize various diagnostic tools and technologies in their practice, such as SAS version 9.4 for data analysis, LOGIQ S8 and LOGIQ E ultrasound systems for imaging, MyLab Twice for musculoskeletal ultrasound, Axio Imager M2 microscopes, RNAlater for sample preservation, and Zen Pro software for image processing.
These advanced solutions help rheumatologists accurately diagnose, monitor, and manage a range of rheumatic disorders.
Additionally, the STACIA® MEBLux™ CCP test can be used to detect rheumatoid arthritis, a common inflammatory condition within the rheumatology field.
With their specialized knowledge and access to cutting-edge technologies, rheumatologists play a crucial role in improving the lives of patients living with debilitating rheumatic conditions.